(Q47702888)

English

Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study

scientific article published in July 1998

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/9699906

Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study (English)

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/9699906

0 references

author name string

Yoshida H

1

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/9699906

Ishikawa T

2

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/9699906

Ayaori M

3

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/9699906

Shige H

4

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/9699906

Ito T

5

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/9699906

Suzukawa M

6

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/9699906

Nakamura H

7

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/9699906

publication date

1 July 1998

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/9699906

Atherosclerosis

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/9699906

139

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/9699906

1

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/9699906

179-187

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/9699906

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

Effect of gemfibrozil on composition of lipoproteins and distribution of LDL subspecies

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

Role of oxidized low density lipoprotein in atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

Enzymatic methods for quantification of lipoprotein lipids

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

Quantitation of serum apolipoprotein A-I, A-II, B, C-II, C-III and E in healthy Japanese by turbidimetric immunoassay: reference values, and age- and sex-related differences

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

Simultaneous determination of α-tocopherol and retinol in plasma or red cells by high pressure liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

Effects of oleate-rich and linoleate-rich diets on the susceptibility of low density lipoprotein to oxidative modification in mildly hypercholesterolemic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

Continuous monitoring of in vitro oxidation of human low density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

Vitamin E/lipid peroxide ratio and susceptibility of LDL to oxidative modification in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

Relations of plasma TG and HDL-C concentrations to body composition and plasma insulin levels are altered in men with small LDL particles.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

Inhibition of low density lipoprotein oxidation in vitro by the 6- and 7-hydroxy-metabolites of doxazosin, an alpha 1-adrenergic antihypertensive agent

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

Effects of various natural antioxidants on the Cu(2+)-mediated oxidative modification of low density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

The inhibition of the oxidation of low density lipoprotein by (+)-catechin, a naturally occurring flavonoid

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

Effect of tea flavonoid supplementation on the susceptibility of low-density lipoprotein to oxidative modification

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900062-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0021-9150(98)00062-8

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/9699906

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/9699906

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47702888&oldid=2166221864"